Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, has been shown to have anti-tumor effect on solid tumor whereas the anti-CML effect and its underlying mechanism have not been completely elucidated. The gene discussed is PTGS2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.